Michael E. Burczynski
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 8
- Cell Biology top 1%
- Aldose Reductase and Taurine 13
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism 7
- Molecular Biology top 5%
- Gene expression and cancer classification 7
- Heme Oxygenase-1 and Carbon Monoxide 6
-
- Drug Transport and Resistance Mechanisms 6
-
- Prenatal Substance Exposure Effects 6
-
- Computational Drug Discovery Methods 5
Michael E. Burczynski
49 papers receiving 4.2k citations
Hit Papers
Peers
Comparison fields: 5 of 139
- Cancer Research 942
- Cell Biology 926
- Pharmacology 280
- Endocrinology, Diabetes and Metabolism 532
- Molecular Biology 2.1k
Countries citing papers authored by Michael E. Burczynski
This map shows the geographic impact of Michael E. Burczynski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Burczynski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Burczynski more than expected).
Fields of papers citing papers by Michael E. Burczynski
This network shows the impact of papers produced by Michael E. Burczynski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Burczynski. The network helps show where Michael E. Burczynski may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michael E. Burczynski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 72 | |
| 2 | 2018 | 35 | |
| 3 | 2012 | 169 | |
| 4 | 2012 | 385 | |
| 5 | 2011 | 22 | |
| 6 | 2009 | 40 | |
| 7 | 2009 | 61 | |
| 8 | 2009 | 96 | |
| 9 | Src pathway activation correlates with treatment resistance in breast cancer and identifies patient subsets predicted to benefit from Src inhibition | 2008 | 1 |
| 10 | 2008 | 34 | |
| 11 | 2008 | 6 | |
| 12 | 2008 | 4 | |
| 13 | 2008 | 14 | |
| 14 | 2008 | 43 | |
| 15 | 2006 | 191 | |
| 16 | 2005 | 68 | |
| 17 | 2001 | 94 | |
| 18 | 2001 | 29 | |
| 19 | 2001 | 82 | |
| 20 | Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1‒AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormonesbreakdown → | 2000 | 505 |
About Michael E. Burczynski
Michael E. Burczynski is a scholar working on Cancer Research, Cell Biology and Pharmacology, having authored 50 papers that have together received 4.3k indexed citations. Recurring topics across this work include Aldose Reductase and Taurine (13 papers), Cancer Genomics and Diagnostics (8 papers), Pharmacogenetics and Drug Metabolism (7 papers), Gene expression and cancer classification (7 papers), Drug Transport and Resistance Mechanisms (6 papers), Prenatal Substance Exposure Effects (6 papers), Heme Oxygenase-1 and Carbon Monoxide (6 papers) and Computational Drug Discovery Methods (5 papers). The work is most often cited by research in Cancer Research (942 citations), Cell Biology (926 citations) and Pharmacology (280 citations). Michael E. Burczynski has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include T.M. Penning, Nisha Palackal, Chien‐Fu Hung, Holly Hilton, Saumya Pant, Andrew J. Dorner, Haiching Ma, Margaret Moore, Joseph M. Jez and Kapila Ratnam. Their work appears in journals such as Biochemistry, Clinical Cancer Research, Molecular and Cellular Endocrinology, Alzheimer s & Dementia and Pharmacogenomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.